Table 2 Loss of FADD in ex vivo NSCLC

From: FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer

  

Tumour biopsies intracellular FADD expression a

Patients

Stage

Tumour

Alveolar EC

Bronchial EC

35

I

3

np

np

31

I

3

1

3

77

I

1.5

0 and 1 near T

3

76

I

2

0.5

3

69

I

1.5

0

3

Mean stage I

2.2

0.5

3

44

II

0

0 and 1 Hyp

3

70

II

0.5

0

np

30b

II

3/ 0 LNM

2/ 0

3/ 2

55b

II

0.5/ np

0/ np

2/ 3

50

II

0.5

0

np

48b

II

1/ np

0.5/ 0

1/1

Mean stage II

0.8

0.4

2.1

37

III

2

0

np

33

III

3

1

3

49

III

2

0

3

86b

III

3/3

0.5/ np

2/ 3

83

III

0 and 2 VE

0.5

3

82b

III

2/ np

2/ 0

2.5/ 2

68b

III

2/2

np/ np

np/ np

61b

III

1.5/np

0/ 0

3/ 1

87

III

np

0

3

88b

III

np/2

2/ np

3/ 3

59b

III

np/0.5

0 and 2 Hyp/ 1

3/ 3

46

III

1

1.5

2

28b

III

1/ np

0/ 0

np/ np

Mean stage III

1.8

0.6

2.6

  1. Abbreviations: EC=epithelial cells; FADD=Fas-associated death domain protein; np=structure not present in the section; Hyp=hyperplasia; LNM=lymph node metastasis; VE=vascular emboli; T=tumour.
  2. Correlation between patients' cancer stage and FADD expression in T area determined by IHC. All patients were treated at the Hôtel-Dieu hospital.
  3. a0, neg; 0.5, ±; 1, +; 1.5, +/++; 2, ++; 2.5, ++/+++; 3, +++.
  4. bIndicates that two samples of a same biopsy were embedded in distinct paraffin blocks that were sectioned and analysed.
Back to article page